---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-22-010767"
form_type: "8-K"
ticker: "CVM"
cik: "0000725363"
company_name: "CEL SCI CORP"
filed_at: "2022-08-08T23:59:59+00:00"
generated_at: "2026-06-24T03:04:57.158696+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# CEL-SCI appoints Gail K. Naughton, Ph.D. to Board of Directors

## Summary
- Dr. Naughton founded Advanced Tissue Sciences (ATIS) and Histogen (HSTO), with 35+ years in regenerative medicine.
- She holds over 125 U.S. and foreign patents and received the National Inventor of the Year award in 2000.
- She serves on boards of Therapeutics MD (TXMD) and chairs the La Jolla Institute for Immunology board.
- Appointment effective August 2, 2022.

## SEC filing metadata
- accession: 0001654954-22-010767
- form_type: 8-K
- ticker: CVM
- cik: 0000725363
- company_name: CEL SCI CORP
- filed_at: 2022-08-08T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/725363/000165495422010767/0001654954-22-010767-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/725363/000165495422010767/cvm_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-22-010767
- JSON: https://secwatch.observer/filing/0001654954-22-010767.json
- Plain text: https://secwatch.observer/filing/0001654954-22-010767.txt

## Key facts
- Executive change
  Gail K. Naughton, Ph.D. was appointed as Director at CEL SCI CORP.
  - Action: appointed
  - Role: Director
  source text: On August 2, 2022, CEL-SCI Corporation appointed Gail K. Naughton, Ph.D. to its Board of Directors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/725363/000165495422010767/0001654954-22-010767-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.